Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Moderna

Pfizer

The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.

US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch

Zoom Video

California Public Employees Retirement System (CalPERS) disclosed Wednesday that it more than doubled its shares stakes in Gilead Sciences Inc.

CalPERS more than doubles Gilead and Zoom Video stakes, trims Apple and Microsoft

Automatic Data Processing

Franklin Resources

Medtronic

Pinnacle West Capital

Starbucks

Snap-on

Toronto-Dominion Bank

10 Dividend Growth Stocks For August 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc.

China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

Gilead Sciences, Inc (NASDAQ: GILD) announced Monday it was seeking complete Food and Drug Administration approval for its drug Remdesivir, which is being used in the treatment of COVID-19.

Gilead Seeks Full FDA Approval Of Its Remdesivir Drug For Coronavirus

Right now, the antiviral is being administered to coronavirus patients under an emergency use authorization, which is more limited.

Gilead Sciences Submits New Drug Application for Remdesivir as a COVID-19 Treatment

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19

Dynavax Technologies

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

AstraZeneca

iShares Nasdaq Biotechnology ETF

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.

Biotech's Q2:  Lots Of Candidates That May Deliver Alpha

Abbott Labs

No one wants COVID-19 vaccines to fail. But if you want to hedge for the possibility, check out these solid stocks.

3 Large-Cap Stocks That Should Soar If Coronavirus Vaccines Flop

The company is pitching in to produce Gilead's antiviral treatment, which received emergency use authorization in May.

Pfizer to Co-Manufacture Coronavirus Drug Remdesivir

Large-cap biopharma companies Pfizer Inc. (NYSE: PFE) and Gilead Sciences, Inc. (NASDAQ: GILD) announced a deal Friday for GIlead's remdesivir, which has been accorded emergency use authorization by the FDA for treating COVID-19.

Pfizer, Gilead Strike Multiyear Partnership To Manufacture COVID-19 Drug Remdesivir

The buddy system will help the pharmaceutical companies quickly ramp up production, even as the coronavirus continues to spread.

Pharma Giant Pfizer Teams With Gilead To Boost Production Of Covid-19 Drug Remdesivir

The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.

NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment

Pfizer has agreed to manufacture and supply Gilead Sciences’ antiviral drug remdesivir, the pharmaceutical giant announced Friday.

Pfizer agrees to manufacture Gilead's coronavirus drug remdesivir

Shares of Pfizer Inc. PFE, -0.46% gained 1.0% in premarket trading on Friday after it announced that it will help manufacture Gilead Sciences Inc.

Pfizer to help manufacture Gilead's remdesivir

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc.

Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

Gilead said it plans to produce more than 2 million treatment courses of the drug by the end of the year and anticipates being able to produce "several million more" in 2021.

Gilead says it will be able to make enough remdesivir to meet global coronavirus demand in October

Taking a deeper look into the reasons why Gilead underperformed the last quarter.

Has Gilead Dipped Too Low?

BioCryst Pharmaceuticals

A Neglected Treatment Space For COVID-19

Both big drugmakers have the potential to make billions from their COVID-19 programs.

Better Coronavirus Stock: Gilead Sciences or Pfizer?

Alexion Pharma

Royalty Pharma

The biopharmaceutical industry has been one of the most resilient in dealing with the coronavirus pandemic.

5 Large Biotechs and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Gilead Sciences - Now That The COVID-19 Hype Is Over, Take A Look

News for Gilead Sciences Stock (GILD)